FDA Inspection 1220703 — Eagle Pharmaceuticals, Inc.
The FDA completed an inspection of Eagle Pharmaceuticals, Inc. on Oct 13, 2023 in Woodcliff Lake, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Oct 13, 2023
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Woodcliff Lake, NJ (United States)
Additional details
Postmarket Adverse Drug Experience (PADE)